Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints

Author:

Yang Jiaying1,Li Jingxin2,Wang Shiyuan1,Luo Li1,Liu Pei1ORCID

Affiliation:

1. Department of Epidemiology and Biostatistics, Southeast University, Nanjing, China

2. Jiangsu Province Center for Disease Control and Prevention, Nanjing, China

Funder

Postgraduate Research * Practice Innovation Program of Jiangsu Province

the Fundamental Research Funds for the Central Universities and Postgraduate Research Practice Innovation Program of Jiangsu Province

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference35 articles.

1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry for the evaluation of combination vaccines for preventable diseases: production, testing and clinical studies. 1997 April accessed 2017 Oct 21. https://wwwfdagov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm175909pdf 1997.

2. Elsevier, Inc. “polyvalent vaccine”. Saunders comprehensive veterinary dictionary, 3 ed. 2007 accessed 2017 Nov. https://medical-dictionary.thefreedictionary.com/polyvalent+vaccine.

3. Multiparameter Hypothesis Testing and Acceptance Sampling

4. Challenge of multiple co-primary endpoints: a new approach

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3